Combining therapies to treat atypical neurofibromas in neurofibromatosis type 1
Official title: Preclinical-clinical trials collaboration to effectively advance new combination therapies for atypical neurofibroma in neurofibromatosis type 1
Funded at Indiana University Indianapolis · NIH-11035064 · Data updated 2026-11-12
This study is looking for better ways to treat atypical neurofibromas in people with neurofibromatosis type 1 (NF1) to help stop them from turning into more serious tumors, and patients may have the chance to try out these new treatments.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | February 7, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $316,195 |
| NIH project number | 5U01CA278474-03 |
| Project ID | NIH-11035064 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 1 who have atypical neurofibromas.
✕Less likely to help
Patients without neurofibromatosis type 1 or those who do not have atypical neurofibromas may not benefit from this research.
What this research studies
This research focuses on developing new combination therapies for atypical neurofibromas in patients with neurofibromatosis type 1 (NF1). It aims to understand the progression from benign plexiform neurofibromas to malignant peripheral nerve sheath tumors, which are aggressive and often fatal. By collaborating with various clinical and preclinical teams, the project seeks to identify effective treatment strategies that can prevent the transformation of atypical neurofibromas into malignant tumors. Patients may be involved in trials that test these new therapies to improve outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments that prevent the progression of atypical neurofibromas to malignant tumors, improving survival rates for patients with NF1.
How similar studies have gone: Previous research has shown promising results in treating NF1-associated tumors, but this specific approach to atypical neurofibromas is novel and untested.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Clapp, David W — Indiana University Indianapolis
- Study coordinator: Clapp, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.